News Sentiment

RIGL sentiment intelligence

Rigel Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 32.91 Week of 19 Jun 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+0.2% over one week, +13.4% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL)

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 0.2% Price digesting
Trend fit Trend inactive 13.4% over four weeks
Fair value 59.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 39
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 10
simplywall.st 8
PR Newswire 4
Seeking Alpha 3
Stock Traders Daily 3
TradingKey 3
Benzinga 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 19
Deals and strategy 6
Balance sheet 3
Analyst action 3
Guidance 3
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Stock Traders Daily Direct company coverage

Liquidity Mapping Around (RIGL) Price Events

This article from Stock Traders Daily analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models to provide trading strategies and signals. It details key findings including sentiment analysis, risk-reward scenarios, and support/resistance levels across different time hor

Tone
Positive 74/100
Event
Balance sheet
Published
20 Jun 2026 01:14
Source
Stock Traders Daily
The Globe and Mail Direct company coverage

Rigel Expands Oncology Portfolio with VEPPANU Global Rights

Rigel Pharmaceuticals has acquired exclusive global rights for VEPPANU (vepdegestrant) through an agreement with Arvinas, Inc. and Pfizer Inc. This $70 million upfront payment expands Rigel's oncology pipeline. While analysts rate RIGL stock a "Buy" with a $57.00 target, TipRanks

Tone
Positive 70/100
Event
Analyst action
Published
19 Jun 2026 12:38
Source
The Globe and Mail
TradingKey Direct company coverage

Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Rigel Pharmaceuticals Inc (RIGL), noting its strong financial status and high operating efficiency. The company's current financial score is 7.99, placing it well within the pharmaceuticals industry. Rigel recently reported a 1

Tone
Positive 71/100
Event
Market update
Published
18 Jun 2026 00:39
Source
TradingKey
TradingKey Direct company coverage

Rigel Pharmaceuticals Inc (RIGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey reports on Rigel Pharmaceuticals Inc (RIGL), noting its current stock price, market capitalization, and P/E ratio. The primary focus of the article is the company's revenue breakdown; however, it states that relevant data for business segments, region

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 14:10
Source
TradingKey
Bitget Direct company coverage

According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improv

Arvinas Holding Company LLC, Pfizer, and Rigel Pharmaceuticals have received approval under the Hart–Scott–Rodino Antitrust Improvements Act on June 11, 2026. This approval removes regulatory hurdles for their previously announced licensing agreement, allowing them to advance the

Tone
Positive 67/100
Event
Regulatory and legal
Published
16 Jun 2026 23:10
Source
Bitget
PR Newswire Direct company coverage

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Rigel Pharmaceuticals, Inc. announced the closing of its licensing agreement for VEPPANU™ (vepdegestrant) with Arvinas, Inc. and Pfizer Inc. The agreement, effective as of June 11, 2026, followed the early termination of the Hart-Scott Rodino waiting period. Rigel made an upfront

Tone
Positive 72/100
Event
Market update
Published
16 Jun 2026 20:10
Source
PR Newswire
Stock Traders Daily Direct company coverage

Why (RIGL) Price Action Is Critical for Tactical Trading

This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) stock, highlighting a neutral near and mid-term outlook but a strong long-term positive bias. It presents several AI-generated trading strategies, including long, momentum breakout, and short options, along with key

Tone
Negative 39/100
Event
Guidance
Published
09 Jun 2026 00:06
Source
Stock Traders Daily
Benzinga Direct company coverage

Insider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel Pharmaceuticals

Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals, exercised stock options worth $52,271 for 3,381 shares. The company shows positive revenue growth of 10.28% and a high gross margin of 92.17%, but struggles with a high debt-to-equity ratio of 0.11. The article

Tone
Positive 61/100
Event
Earnings
Published
04 Jun 2026 15:09
Source
Benzinga
Stock Titan Direct company coverage

RIGEL (RIGL) EVP Furey uses 877 shares to cover tax obligations

RIGEL PHARMACEUTICALS INC EVP Raymond J. Furey reported a tax-withholding disposition of 877 common shares on June 1, 2026, at $29.86 per share to cover tax obligations. This non-market transaction is classified as a routine tax-withholding disposition, not a discretionary sale.

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 06:10
Source
Stock Titan
Stock Titan Direct company coverage

Rigel (NASDAQ: RIGL) EVP uses shares to cover tax obligations

Rigel Pharmaceuticals EVP and Chief Commercial Officer, David A. Santos, reported a tax-related share disposition. He delivered 874 shares of common stock at $29.86 per share to cover tax obligations, which is a routine tax-withholding event, not an open-market sale. After this t

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Rigel (RIGL) CMO uses 850 shares to cover stock tax liability

Rigel Pharmaceuticals Inc.'s EVP and Chief Medical Officer, Lisa Rojkjaer, disposed of 850 shares of common stock on June 1, 2026, to cover a tax liability. This transaction, valued at $29.86 per share, was a tax-withholding disposition, not an open-market sale or purchase. After

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Rigel Pharmaceuticals (RIGL) CFO exercises options and withholds shares for taxes

Rigel Pharmaceuticals' EVP & Chief Financial Officer, Dean L. Schorno, exercised stock options for 3,381 shares and withheld 928 shares to cover tax obligations. This transaction was a tax-withholding event, not an open-market sale, leaving him with 78,790 directly held shares. A

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake

RIGEL PHARMACEUTICALS INC CEO Raul R. Rodriguez reported a Form 4 transaction where 2,424 shares of Common Stock were delivered on June 1, 2026, at $29.86 per share to cover tax obligations. This disposition is classified as routine tax withholding, not an open-market trade. Foll

Tone
Neutral 50/100
Event
Deals and strategy
Published
03 Jun 2026 21:40
Source
Stock Titan
Simply Wall Street Direct company coverage

Rigel Pharmaceuticals (NasdaqGS:RIGL) Stock Forecast & Analyst Predictions

Rigel Pharmaceuticals (RIGL) is facing a forecast decline in earnings (33.2% per annum) and EPS (43.2% per annum) over the next three years, despite expected annual revenue growth of 6.9%. The company recently acquired global rights to the breast cancer therapy VEPPANU, which is

Tone
Positive 66/100
Event
Earnings
Published
02 Jun 2026 07:39
Source
Simply Wall Street
Simply Wall Street Direct company coverage

RIGL - Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks

Rigel Pharmaceuticals' future opportunities are driven by the expansion of its commercial portfolio and a diversified clinical pipeline, despite risks from product dependence and competition. Analysts have lifted their price target due to updated assumptions around long-term reve

Tone
Positive 63/100
Event
Analyst action
Published
29 May 2026 20:10
Source
Simply Wall Street
Stock Titan Direct company coverage

Rigel Pharmaceuticals (RIGL) director sells 2,500 shares in open-market trade

Rigel Pharmaceuticals director Ali-Jackson Kamil sold 2,500 shares of common stock at an average price of $29.17 per share on May 26, 2026. This open-market transaction falls under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the sale, the director

Tone
Negative 39/100
Event
Market update
Published
29 May 2026 02:39
Source
Stock Titan
GuruFocus Direct company coverage

Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Phar

Kamil Ali-jackson, a Director at Rigel Pharmaceuticals Inc (RIGL), sold 2,500 shares of the company on May 26, 2026, reducing her holdings to 12,625 shares. This sale is part of a trend with no insider buys and two insider sells for RIGL over the last year. The stock is currently

Tone
Negative 38/100
Event
Market update
Published
29 May 2026 02:39
Source
GuruFocus
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (RIGL)

Quantitative analysis for Rigel Pharmaceuticals Inc. (RIGL) shows strong sentiment across all horizons, supporting an overweight bias. The article details three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, ind

Tone
Positive 93/100
Event
Analyst action
Published
28 May 2026 22:39
Source
Stock Traders Daily
Investing.com Direct company coverage

Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock

Rigel Pharmaceuticals director Ali-Jackson Kamil sold 2,500 shares of the company's common stock for a total of $72,925 on May 26, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan. The company recently reported a 26% revenue increase in Q1 2026 and se

Tone
Neutral 50/100
Event
Earnings
Published
28 May 2026 20:39
Source
Investing.com
GuruFocus Direct company coverage

Rigel Pharmaceuticals (RIGL) CEO to Present at Jefferies Global Healthcare Conference

Rigel Pharmaceuticals (RIGL) CEO, Raul Rodriguez, will present at the Jefferies Global Healthcare Conference on June 3, 2026, to highlight the company's advancements in biotechnology. While the stock is currently slightly overvalued according to its GF Value, its GF Score of 78 i

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 20:10
Source
GuruFocus
PR Newswire Direct company coverage

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Pharmaceuticals, Inc. announced that its President and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference. The presentation is scheduled for Wednesday, June 3, 2026, at 8:45 a.m. ET in New York. A live webcast and archived rec

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 12:09
Source
PR Newswire
Stock Titan Direct company coverage

Biotech CEO to give Rigel company overview at Jefferies healthcare conference

Rigel Pharmaceuticals (Nasdaq: RIGL) announced that its President and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference on June 3, 2026, in New York. The presentation will be webcast live and available for replay on Rigel's investo

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

[144] RIGEL PHARMACEUTICALS INC SEC Filing

This article details an SEC Form 144 filing by RIGEL PHARMACEUTICALS INC (RIGL) regarding a proposed sale of securities. The filing indicates a sale of 2,500 common shares by an individual with an aggregate market value of $72,925.00, acquired through restricted stock vesting as

Tone
Neutral 50/100
Event
Market update
Published
26 May 2026 14:40
Source
Stock Titan
PR Newswire Direct company coverage

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Rigel Pharmaceuticals, Inc. announced upcoming oral and poster presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress, showcasing data for GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib). The presentations will include final data from the Phase 3 AcceleRET-Lung c

Tone
Positive 71/100
Event
Market update
Published
21 May 2026 21:40
Source
PR Newswire
Stock Titan Direct company coverage

RIGEL (NASDAQ: RIGL) director receives 5,750-share Restricted Stock Unit grant

RIGEL Pharmaceuticals Inc. director Alison L. Hannah received a grant of 5,750 Restricted Stock Units (RSUs) as a compensation-related award, not a market purchase. These RSUs, which represent common stock shares, will fully vest on the day before the company's next Annual Meetin

Tone
Neutral 50/100
Event
Market update
Published
20 May 2026 23:40
Source
Stock Titan